DrosoPharma - the future of behavioral engineering

Extreme-throughput discovery of drugs, nutraceuticals, compounds, and genetic targets that alter behavior, including behavioral and cognitive pathologies that arise from aging, neurological disease or lifestyle

Explore More

The vision

Long life is no longer enough

Human lifespan is increasing, but the onset of our cognitive, locomotor and behavioral healthspan has remained unchanged.

We are dedicated to the future where the average human life is not just longer, but enduringly prosperous.

We use robotics-assisted extreme scale-up of genetic, pharmacological, nutritional engineering of cognitive behavior in humanized in vivo models to push the limits of healthspan.

The challenge

Learn More

Identifying causes of behavioral pathology

Behavioral neuroscience has failed at identifying in vitro molecular biomarkers or drug targets to diagnose behavioral pathology.

The only consistent and reliable early biomarker for neuronal disease is behavior.

However, automated quantification of behavior has been exceptionally technologically challenging, costly, and unethical to measure at the scale necessary for serendipitous discovery.

Consequently, there are currently no cures or even long-term management strategies for most neuronal behavioral pathologies, including age-dependent cognitive deterioration, dementia, neurodegenerative locomotor disability, addiction and mental health issues that affect hundreds of millions world-wide.

Driven by a passion for disruptive innovation and scientific excellence, we aim to revolutionize pharmaceutical research and drug discovery aimed at treating behavioral and cognitive deterioration caused by aging, disease or lifestyle. We are dedicated to advancing neuroscience, disrupting neuropharmacology , and shaping the future of behavioral studies.

The mission

In vivo behavior screens at the scale of disruptive discovery

We aim to develop a customizable platform for extreme-throughput pharmaceutical, nutraceutical and genetic screens and discovery.

We focus on modifiers of neurological disorders with behavioral pathologies that can be as simple as locomotor ability and as complex as cognition.

Our focus is on preclinical screens for compounds of interest or genetically encoded drug targets for treating behavioral symptoms in disease and aging.

We evaluate their impact on behavioral healthspan in humanized disease models in Drosophila, at a 100-fold higher scale and 100-fold lower cost than

Technology

Robotic Drug Screening

Our advanced robotic systems enable precise and efficient drug screening processes at unprecedented throughput, ensuring accurate and reliable results. By integrating cutting-edge robotics and behavioral technology with scientific rigor, we enhance the speed and accuracy of drug discovery for neurological disorders, setting new standards in both research and industry.

We utilize state-of-the-art robotics to conduct high-throughput drug screens, allowing for comprehensive analysis of compounds and their effects on behavioral and neurological models. Our technology-driven approach accelerates research outcomes and facilitates breakthroughs in pharmaceutical development.